Spry Bio, Inc.
October 18, 2023
Company Description: Spry Bio, Inc. is a pre-clinical biotechnology company developing Optimized Platelet Therapies (OPTs) for treating osteoarthritis (OA) and other medical conditions characterized by poor vascularization. Spry Bio combines an experienced drug development team with experts in platelet biology, regenerative medicine, and orthopedics. The Company is raising a $3M seed round to develop its first pre-clinical candidate, OPT-OA for treating knee OA, a common and painful condition with few safe and effective treatment options.
http://www.sprybio.com (currently a holding page pending a full site in development)
CEO/Top Company Official
Terence S. Russell, Ph.D.
Lead Product in Development
OPT-OA: Optimized platelet therapy for knee osteoarthritis
Development Phase of Primary Product